Incorporated in Delaware, Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them. The therapies developed by Arrowhead make use of a broad portfolio of RNA chemistries and efficient modes of delivery to trigger an RNA interference mechanism that induces the rapid and durable knockdown of the target genes.
RNA interference or (RNAi) is a mechanism that inhibits the expression of a specific gene. Through this inhibition of a specific gene, the production of a specific protein can be stopped.
The discoverers of RNAi were awarded a Nobel Prize in 2006 for this work. Their discovery is deemed to be one of the most important recent discoveries in life sciences, and it has the potential to transform medicine.
Of the five analysts covering Arrowhead Pharmaceuticals in January 2018, two have given the stock a “buy” or higher rating, while three have given it a “hold” rating. The mean rating for the stock is 2.4, and its target price is $3.5.
Arrowhead Pharmaceuticals makes up ~0.22% of the Vanguard Global ex-U.S. Real Estate ETF’s (VNQI) total portfolio holdings.
Of the 29 analysts covering Gilead Sciences (GILD) in January 2018, 15 have given the stock a “buy” or higher rating, while the remaining 14 have given the stock a “hold” rating. The mean rating for the stock is 2.34, and it has a target price of $86.13.
All four of the analysts covering Ignyta (RXDX) in January 2018 have given the stock a “hold” rating. The mean rating for the stock is 3, and it has a target price of $28.
All eight of the analysts covering Loxo Oncology (LOXO) in January 2018 have given the stock a “buy” or higher rating. The mean rating for the stock is 1.38, and its target price is $11.83.
In the next article, we’ll take a look at Arrowhead Pharmaceuticals’ TRiM platform.